Cabaletta Bio, Inc.
CABA$309M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPHILADELPHIA
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CABA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy
CABA-201
Generalized Myasthenia Gravis (gMG)
DSG3-CAART
Pemphigus Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CABA-201 following preconditioning with fludarabine and cyclophosphamide | Phase 3 | Idiopathic Inflammatory Myopathy | - | - |
CABA-201 | Phase 2 | Generalized Myasthenia Gravis (gMG) | - | - |
DSG3-CAART | Phase 2 | Pemphigus Vulgaris | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply